Early access
Sign in
Taking people in NetherlandsPhase 1

Tests new agent NRG5051 for safety in Parkinson's and ALS

Tests the new agent NRG5051 in healthy adults and people with Parkinson's or ALS.

Key facts

Who runs it
Nrg Therapeutics Limited
Where
Leiden, NetherlandsSee the site
Registry title
Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS
Status
Recruiting
Phase
Phase 1
People taking part
118 people, planned
Started
18 Nov 2025
Planned end
3 Nov 2026
Type of study
Interventional
Record updated
9 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults and adults with Parkinson's disease or ALS to test the safety of a new agent, NRG5051.

Age
18 years or older
Sex
All sexes can join

Where in Netherlands

  • Centre for Human Drug ResearchLeiden, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests new agent NRG5051 for safety in Parkinson's and ALSGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
9 July 2026